Literature DB >> 9394796

A role for the VLA-4 integrin in the activation of human memory B cells.

A Silvy1, P Altevogt, P Mondière, C Bella, T Defrance.   

Abstract

It is generally recognized that activation through membrane effector molecules such as CD40 or the B cell receptor (BCR) is mandatory to allow B cells to proliferate and differentiate into antibody (Ab)-secreting cells in response to cytokines. We show here that purified tonsillar B cells can be stimulated directly by a cytokine combination to proliferate and secrete immunoglobulins when cultures are performed at high cell density. The contact-mediated activation of B cells in this experimental system is strongly inhibited both by anti-very late antigen (VLA)-4 monoclonal Ab and by a peptide containing the LDV sequence specifically recognized by the alpha 4 integrin binding site. These reagents also significantly suppressed the B cell responses elicited by engagement of the BCR or CD40. Our data reveal that memory B cells but not virgin or germinal center B cells are sensitive to the direct stimulatory effect of cytokines in high-density cultures. Finally, we found that the dual expression of the alpha and beta chains of VLA-4 is a distinctive feature of the memory B cell population. Collectively, our findings support the notion that VLA-4-dependent homotypic B cell interactions can mediate a co-stimulatory signal to human memory B cells and might participate in the B cell activation triggered through the BCR and CD40.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394796     DOI: 10.1002/eji.1830271103

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Authors:  Marek Mraz; Clive S Zent; Amy K Church; Diane F Jelinek; Xiaosheng Wu; Sarka Pospisilova; Stephen M Ansell; Anne J Novak; Neil E Kay; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

2.  Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

Authors:  B E Theien; C L Vanderlugt; T N Eagar; C Nickerson-Nutter; R Nazareno; V K Kuchroo; S D Miller
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

3.  Different roles for LFA-1 and VLA-4 integrins in T-B-cell interactions in vivo.

Authors:  M López-Hoyos; C Revilladagger; C Conde; E G Del Campo; A González; J Merino
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

4.  Nurse-like cells from bone marrow and synovium of patients with rheumatoid arthritis promote survival and enhance function of human B cells.

Authors:  Y Shimaoka; J F Attrep; T Hirano; K Ishihara; R Suzuki; T Toyosaki; T Ochi; P E Lipsky
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

5.  Dissecting Integrin Expression and Function on Memory B Cells in Mice and Humans in Autoimmunity.

Authors:  Alessandro Camponeschi; Natalija Gerasimcik; Ying Wang; Timothy Fredriksson; Dongfeng Chen; Chiara Farroni; Katrin Thorarinsdottir; Louise Sjökvist Ottsjö; Alaitz Aranburu; Susanna Cardell; Rita Carsetti; Inger Gjertsson; Inga-Lill Mårtensson; Ola Grimsholm
Journal:  Front Immunol       Date:  2019-03-21       Impact factor: 7.561

6.  Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β.

Authors:  Úrsula Muñoz; Cristina Sebal; Esther Escudero; Elena Urcelay; Rafael Arroyo; Maria A García-Martínez; Francisco J Quintana; Roberto Álvarez-Lafuente; Maria Cruz Sádaba
Journal:  Sci Rep       Date:  2022-08-03       Impact factor: 4.996

7.  Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis.

Authors:  Ranjani Ganapathy Subramanian; Dana Horakova; Manuela Vaneckova; Balazs Lorincz; Jan Krasensky; Eva Kubala Havrdova; Tomas Uher
Journal:  Diagnostics (Basel)       Date:  2021-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.